Tuesday, May 10, 2011
Chelsea Therapeutics International Ltd., of Charlotte, N.C., said an independent data safety monitoring board recommended continuation of its ongoing Phase II trial of CH-4051 in rheumatoid arthritis and that it should initiate enrollment in the 3-mg dose group. Ten patients have completed treatment in the 0.3-mg and 1-mg dose cohorts, with no negative safety signals found by the DSMB. For the remainder of the trial, patients will be randomized to 0.3 mg, 1 mg or 3 mg of CH-4051 daily, 3 mg CH-4051 daily with folate supplement, or methotrexate weekly with folate supplement for 12 weeks.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.